<DOC>
	<DOCNO>NCT03057314</DOCNO>
	<brief_summary>To improve function welfare late stage solid cancer subject : - enable subject benefit potentially promising drug development - assess initial evidence improvement Pain VAS score - assess initial improvement Performance Status ( PS ) - assess initial improvement oxygen saturation whenever feasible</brief_summary>
	<brief_title>Improving Function Welfare Late-stage Solid Cancer Subjects ACC Administered Orally Concomitantly With Inhalation</brief_title>
	<detailed_description />
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>1 . Males female , Age &gt; 18 year 2 . Signed informed consent 3 . Late Stage Histologically proven advance solid tumor standard curative therapy exist , fail refused anticancer treatment 4 . Performance Status : ECOG 01 5 . No brain metastasis CT MRI 6 . Life Expectancy : least 2 month 7 . Hormonal therapy allow need 8 . Patient conservative treatment relieve symptom 9 . Subjects within normal range serumcorrected albumin calcium 10 . Acceptable haematology biochemistry variable : WBC &gt; 3000/mm3 Absolute Neutrophil count &gt; 1500 /mm3 Platelet Count &gt; 100,000/mm3 Hemoglobin &gt; 9 g/dL Bilirubin &lt; 1.5 time ULN ALT AST &lt; 2 time ULN PT/PTT &lt; 1.5 ULN 11 . Subjects must Vitamin D sufficient upon study entry , define 25 ( OH ) D serum level &gt; 20 ng/mL ( 50 nmol/L ) accord document compose Food Nutrition Board Institute Medicine , USA . If subject Vitamin D insufficient deficient , load dose Vitamin D3 administer follow : 1 . If serum 25 ( OH ) D level 1220 ng/mL ( 3050 nmol/L ) load oral dose 50,000 IU Vitamin D3 administer twice 35 day dos . 2 . If serum 25 ( OH ) D level â‰¤ 12 ng/mL ( 30 nmol/L ) , load oral dose 50,000 IU Vitamin D3 administer three time 35 day dos . Serum 25 ( OH ) D level check 12 week follow last loading . 12 . Regardless Vitamin D level , subject receive daily maintenance dose 1000 IU Vitamin D3 , take morning breakfast . 13 . Subjects receive Denosumab bisphosphonates eligible provide treatment initiate least 2 week prior study enrollment . 14 . Negative Pregnancy Test 1 . Concurrent treatment acute anticancer therapy 2 . Hypercalcemia 3 . Any illness condition deem physician contraindicate treatment ACC may interfere assessment therapy 4 . Active History Brain Metastases . 3 . Clinical Significant Cardiovascular Disease 4 . Known alcohol drug abuse 5 . Any psychiatric condition would prohibit understanding rendering Informed Consent 6 . Active Participation Clinical Trial last 2 week prior inclusion 7 . Subjects receive Denosumab bisphosphonates eligible provide treatment initiate less 2 week prior study enrolment 8 . Persistent Toxicity relate prior therapy great 2 NCICTCAE v 4.0 9 . Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>